Diana Gallagher, M.D. (Observer)

Diana Gallagher is the head of Multiple Sclerosis and Immunology Disease Unit and External Innovation at Biogen. Her group in External Innovation identifies opportunities to augment the Biogen portfolio covering U.S. and global regions, with efforts ranging from smaller collaborations with academia, to larger partnerships or acquisitions, and strategic investments. In this role, she works closely with corporate development and the transactions team. Dr. Gallagher joined Biogen in 2015 and has worked across discovery and clinical development with a focus on building emerging areas, including ophthalmology, immunology, and neuropsychiatry. She was an R&D leader for the recent acquisition of Nightstar Therapeutics, an ocular gene therapy company. Prior to Biogen, Dr. Gallagher worked in early clinical development at Merck on oral, IV, and inhaled products across a range of clinical indications. Dr. Gallagher earned her M.D. at Johns Hopkins University School of Medicine and a M.S. in medical sciences at Harvard Medical School. She completed an internal medicine residency and a fellowship in pulmonary and critical care at the Harvard hospitals.